Alertix Veterinary Diagnostics AB was founded in 2017. We operate from Stockholm, Sweden, and our research is conducted in the university town of Uppsala. Our local partners are located across EU and the US.

Our goal is to develop discoveries from Swedish veterinary medical biotech research. In particular concerning a new, powerful method for measuring the presence of the enzyme thymidine kinase 1 (TK1) in serum of animals important in veterinary medicine. TK1 is a biomarker for tumor growth and cell turnover. The substance has been detected in serum of patients even before they show clinical symptoms. This means that the assay can be a valuable tool for early diagnosis of cancer diseases. Unlike previously established methods for detecting TK1 the Alertix method is an immunochemical routine method, which can also successfully detect serum TK1 in patients with solid tumors.

Alertix is developing a TK1 assay for dogs, cats & horses under the brandname Predipet, that is based on standard analysis platforms. It is a robust and cost-efficient tool for diagnosing, monitoring and screening tumor diseases. The development of assays for dogs is ready for launch and cats and horses are in progress.

Predipet is patented (or pending) in Australia, Japan, China, US, Canada, and unitary patented in EU incl UK.